高危局限性前列腺癌男性根治性前列腺切除术前给予[177Lu]Lu-PSMA-617(LuTectomy):单中心、单臂、1/2期研究
本研究为单臂1/2期试验,纳入20例高危局限性前列腺癌患者,术前接受1或2周期[177Lu]Lu-PSMA-617(5 GBq)后行机器人根治性前列腺切除术。主要终点为肿瘤辐射吸收剂量,未发生3/4级毒性或Clavien 3-5级并发症。
要点
- 队列A(n=10)接受1周期、队列B(n=10)接受2周期[177Lu]Lu-PSMA-617(5 GBq),6周后手术。
- 最常见的相关不良事件为1级疲乏8例(40%)、恶心7例(35%)、口干6例(30%)、血小板减少4例(20%)。
- 未发生3/4级毒性或Clavien 3-5级并发症。
核心结论
- 在高危局限性前列腺癌且PSMA高表达男性中,[177Lu]Lu-PSMA-617递送高水平靶向辐射剂量,毒性少且不损害手术安全。
- 作者认为值得在该人群中进一步研究[177Lu]Lu-PSMA-617,以确定能否显示有意义的长期肿瘤学获益。
研究设计与样本
- 单中心、单臂、1/2期试验,纳入20例高危局限性前列腺癌男性(PSA>20 ng/ml、ISUP分级组3-5、≥cT2c任一),[68Ga]Ga-PSMA-11 PET/CT显示高肿瘤摄取且计划行根治性前列腺切除术。
- 队列A(n=10)接受1周期、队列B(n=10)接受2周期[177Lu]Lu-PSMA-617(5 GBq),6周后手术。
- 主要终点为肿瘤辐射吸收剂量;评估不良事件(CTCAE 5.0版)、手术安全性(Clavien-Dindo)、影像学和生化反应(ClinicalTrials.gov: NCT04430192)。
主要发现
- 2020年5月29日至2022年4月28日共入组20例患者;中位PSA为18 ng/ml(IQR 11-35),18例(90%)GG≥3,6例(30%)为N1期疾病。
- 所有病灶第1周期后中位(IQR)最高肿瘤辐射吸收剂量为35.5 Gy(19.5-50.1),前列腺为19.6 Gy(11.3-48.4);5例患者淋巴结接受辐射。
- 9例(45%)患者达到>50% PSA下降。
- 与[177Lu]Lu-PSMA-617相关的最常见不良事件为1级疲乏8例(40%)、恶心7例(35%)、口干6例(30%)、血小板减少4例(20%);未发生3/4级毒性或Clavien 3-5级并发症。
临床怎么用
- 原文未据此给出推荐。
局限性
- 局限性包括样本量小。
- 作者认为值得进一步研究以确定能否显示有意义的长期肿瘤学获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High-risk localised prostate cancer (HRCaP) has high rates of biochemical recurrence; [177Lu]Lu-PSMA-617 is effective in men with advanced prostate cancer. OBJECTIVE: To investigate the dosimetry, safety, and efficacy of upfront [177Lu]Lu-PSMA-617 in men with HRCaP prior to robotic radical prostatectomy (RP). DESIGN, SETTING, AND PARTICIPANTS: In this single-arm, phase I/II trial, we recruited men with HRCaP (any of prostate-specific antigen [PSA] >20 ng/ml, International Society of Urological Pathology (ISUP) grade group [GG] 3-5, and ≥cT2c), with high tumour uptake on [68Ga]Ga-PSMA-11 positron emission tomography/computed tomography (PSMA PET/CT), and scheduled for RP. INTERVENTION: Cohort A (n = 10) received one cycle and cohort B (n = 10) received two cycles of [177Lu]Lu-PSMA-617 (5 GBq) followed by surgery 6 weeks later. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was tumour radiation absorbed dose. Adverse events (AEs; Common Terminology Criteria for Adverse Events (CTCAE) version 5.0), surgical safety (Clavien-Dindo), imaging, and biochemical responses were evaluated (ClinicalTrials.gov: NCT04430192). RESULTS AND LIMITATIONS: Between May 29, 2020 and April 28, 2022, 20 patients were enrolled. The median PSA was 18 ng/ml (interquartile range [IQR] 11-35), Eighteen (90%) had GG ≥3, and six (30%) had N1 disease. The median (IQR) highest tumour radiation absorbed dose after cycle 1 for all lesions was 35.5 Gy (19.5-50.1), with 19.6 Gy (11.3-48.4) delivered to the prostate. Five patients received radiation to lymph nodes. Nine (45%) patients achieved >50% PSA decline. The most common AEs related to [177Lu]Lu-PSMA-617 were grade 1 fatigue in eight (40%), nausea in seven (35%), dry mouth in six (30%), and thrombocytopenia in four (20%) patients. No grade 3/4 toxicities or Clavien 3-5 complications occurred. Limitations include small a sample size. CONCLUSIONS: In men with HRCaP and high prostate-specific membrane antigen (PSMA) expression, [177Lu]Lu-PSMA-617 delivered high levels of targeted radiation doses with few toxicities and without compromising surgical safety. Further studies of [177Lu]Lu-PSMA-617 in this population are worthwhile to determine whether meaningful long-term oncological benefits can be demonstrated. PATIENT SUMMARY: In this study, we demonstrate that up to two cycles of [177Lu]Lu-PSMA-617 given prior to radical prostatectomy in patients with high-risk localised prostate cancer are safe and deliver targeted doses of radiation to tumour-affected tissues. It is tolerated well with minimal treatment-related adverse events, and surgery is safe with a low rate of complications. Activity measured through PSA reduction, repeat PSMA PET/CT, and histological response is promising.
引用
- Eapen RS, Buteau JP, Jackson P, et al. Administering [177Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study. Eur Urol. 2023. PMID: 37891072. doi:10.1016/j.eururo.2023.08.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。